Literature DB >> 12640075

Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma.

L Kloos1, P Sillevis Smitt, C W Ang, W Kruit, G Stoter.   

Abstract

A 68 year old woman developed oculomotor paresis shortly after metastatic progression of her melanoma was discovered. She was then immunised with the tumour antigen MAGE-3 in combination with an immunological adjuvant. During immunisation her symptoms worsened and she developed severe, predominantly proximal axonal motor neuropathy and became bedridden. IgM antibodies against gangliosides GM2, GD3, and GQ1b were detected in serum obtained two weeks before and nine weeks after the onset of symptoms. Immunohistochemically, the patient's IgM reacted with the tumour and co-localised with GQ1b. She improved neurologically following steroid treatment and became ambulatory.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640075      PMCID: PMC1738398          DOI: 10.1136/jnnp.74.4.507

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  3 in total

1.  Partial resolution of acute ascending motor polyneuropathy after enucleation of an eye with metastatic melanoma.

Authors:  G J Ben Simon; J D McCann; N Barth; R A Goldberg; B J Glasgow; B R Straatsma
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

Review 3.  STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.

Authors:  Stella Logotheti; Brigitte M Pützer
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.